Leaf Huang

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA
    Shyh Dar Li
    Division of Molecular Pharmaceutics, Department of Pharmaceutical Sciences, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Mol Ther 16:942-6. 2008
  2. doi request reprint In vivo delivery of RNAi with lipid-based nanoparticles
    Leaf Huang
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599 7571, USA
    Annu Rev Biomed Eng 13:507-30. 2011
  3. pmc Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer
    Yunching Chen
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Biol Chem 285:22639-50. 2010
  4. pmc Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery
    Jun Li
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Control Release 142:416-21. 2010
  5. doi request reprint Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine
    Weili Yan
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    J Control Release 130:22-8. 2008
  6. pmc The targeted intracellular delivery of cytochrome C protein to tumors using lipid-apolipoprotein nanoparticles
    Sang Kyoon Kim
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    Biomaterials 33:3959-66. 2012
  7. doi request reprint Targeted cancer therapy with novel high drug-loading nanocrystals
    Feng Liu
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7360, USA
    J Pharm Sci 99:3542-51. 2010
  8. pmc An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor
    Sumio Chono
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, 2316 Kerr Hall, 311 Pharmacy Lane, Chapel Hill, NC 27599, USA
    J Control Release 131:64-9. 2008
  9. pmc Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy
    Yuan Zhang
    Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7571, USA
    Biomaterials 34:3447-58. 2013
  10. pmc The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome
    Weili Yan
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 2316 Kerr Hall, CB 7360, Chapel Hill, NC 27599 7360, USA
    Int J Pharm 368:56-62. 2009

Research Grants

  1. Interaction of cationic lipids with dendritic cells
    Leaf Huang; Fiscal Year: 2010
  2. LPD Nanoparticles in Anti-Cancer Therapy
    Leaf Huang; Fiscal Year: 2010
  3. Novel nanoparticles for siRNA delivery
    Leaf Huang; Fiscal Year: 2010

Collaborators

Detail Information

Publications61

  1. pmc Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA
    Shyh Dar Li
    Division of Molecular Pharmaceutics, Department of Pharmaceutical Sciences, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Mol Ther 16:942-6. 2008
    ..At the therapeutic dose, the targeted NP showed little local and systemic immunotoxicity and did not decrease the body weight or damage the major organs...
  2. doi request reprint In vivo delivery of RNAi with lipid-based nanoparticles
    Leaf Huang
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599 7571, USA
    Annu Rev Biomed Eng 13:507-30. 2011
    ..Rational designs that address safety concerns and ensure effective delivery will aid the translation of engineered lipid-based nanoparticles toward the clinic in the foreseeable future...
  3. pmc Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer
    Yunching Chen
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Biol Chem 285:22639-50. 2010
    ..The activity and the toxicity of LPD- and LPD-II-mediated therapy are compared...
  4. pmc Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery
    Jun Li
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Control Release 142:416-21. 2010
    ..The untargeted NP showed a very low silencing effect. The new formulation improved the in vitro silencing effect 3-4 folds compared to the previous LPD formulation, but had a negligible immunotoxicity...
  5. doi request reprint Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine
    Weili Yan
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    J Control Release 130:22-8. 2008
    ..Our data elucidated an important mechanism of adjuvant activity of cationic liposome and could facilitate rational design of synthetic lipid based adjuvants and vaccine formulation...
  6. pmc The targeted intracellular delivery of cytochrome C protein to tumors using lipid-apolipoprotein nanoparticles
    Sang Kyoon Kim
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    Biomaterials 33:3959-66. 2012
    ..In addition, MPS-cytC-NP treatment provoked a tumor growth retardation effect in H460 xenograft mice. We conclude that our NP enables targeted, efficacious therapeutic protein delivery for the treatment of lung cancer...
  7. doi request reprint Targeted cancer therapy with novel high drug-loading nanocrystals
    Feng Liu
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7360, USA
    J Pharm Sci 99:3542-51. 2010
    ..The new nanomedicine formulations show clear potential for clinical development because of the excellent antitumor activity, low toxicity, and the ease of scale-up manufacture. The formulation method may apply to other hydrophobic drugs...
  8. pmc An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor
    Sumio Chono
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, 2316 Kerr Hall, 311 Pharmacy Lane, Chapel Hill, NC 27599, USA
    J Control Release 131:64-9. 2008
    ..15-1.2 mg siRNA/kg), while the previously published formulation, LPD-NP (liposome-protamine-DNA nanoparticle), had a much narrow therapeutic window (0.15-0.45 mg/kg)...
  9. pmc Systemic delivery of gemcitabine triphosphate via LCP nanoparticles for NSCLC and pancreatic cancer therapy
    Yuan Zhang
    Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7571, USA
    Biomaterials 34:3447-58. 2013
    ....
  10. pmc The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome
    Weili Yan
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 2316 Kerr Hall, CB 7360, Chapel Hill, NC 27599 7360, USA
    Int J Pharm 368:56-62. 2009
    ....
  11. ncbi request reprint Surface-modified LPD nanoparticles for tumor targeting
    Shyh Dar Li
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Ann N Y Acad Sci 1082:1-8. 2006
    ..The tumor appeared to be the major uptake organ for siRNA formulated in surface-modified LPD. Our encouraging results indicate that surface-modified LPD may be a potent carrier for RNAi-based tumor therapy...
  12. pmc Paclitaxel nanocrystals for overcoming multidrug resistance in cancer
    Yang Liu
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7360, USA
    Mol Pharm 7:863-9. 2010
    ..We envision that further development of this type of nanocrystal will provide a novel strategy for drug delivery and multidrug resistance treatment...
  13. doi request reprint Targeted nanoparticles deliver siRNA to melanoma
    Yunching Chen
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    J Invest Dermatol 130:2790-8. 2010
    ..Thus, the targeted nanoparticles containing c-Myc siRNA may serve as an effective therapeutic agent for melanoma...
  14. pmc Systemic delivery of siRNA via LCP nanoparticle efficiently inhibits lung metastasis
    Yang Yang
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Mol Ther 20:609-15. 2012
    ..Moreover, this targeted LCP NP significantly prolonged the mean survival time of the animals by 27.8% compared to control group without showing any toxicity at the therapeutic dose...
  15. ncbi request reprint Non-viral is superior to viral gene delivery
    Shyh Dar Li
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    J Control Release 123:181-3. 2007
  16. pmc A highly efficient synthetic vector: nonhydrodynamic delivery of DNA to hepatocyte nuclei in vivo
    Yunxia Hu
    The Center for Nanotechnology in Drug Delivery, Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    ACS Nano 7:5376-84. 2013
    ..Though 100-fold lower in activity than that achieved via hydrodynamic injection, this formulation presents as a much less invasive alternative. To our knowledge, this is the most effective synthetic vector for liver gene transfer. ..
  17. pmc Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy
    Yuhua Wang
    Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Mol Ther 21:358-67. 2013
    ....
  18. pmc Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy
    Yunching Chen
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Mol Ther 18:828-34. 2010
    ..When doxorubicin (DOX) and siRNA were co-formulated in LPD-PEG-NGR, an enhanced therapeutic effect was observed...
  19. pmc Tumor-targeted delivery of siRNA by self-assembled nanoparticles
    Shyh Dar Li
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, USA
    Mol Ther 16:163-9. 2008
    ..The serum level of liver enzymes and body weight monitoring during the treatment indicated a low level of toxicity of the formulation. The carrier itself also showed little immunotoxicity (IMT)...
  20. pmc Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine
    Weihsu Chen
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Mol Pharm 5:464-71. 2008
    ..Overall, the improved DOTAP/E7-lipopeptide vaccine described herein showed a significantly enhanced therapeutic effect for the treatment of a cervical cancer model...
  21. ncbi request reprint Several serum proteins significantly decrease inflammatory response to lipid-based non-viral vectors
    Christine C Conwell
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina 27713, USA
    Mol Ther 16:370-7. 2008
    ..These results suggest that a combination of protein content and DNA placement within the structure is responsible for the significantly improved efficacy and decreased inflammatory toxicity of these modified non-viral vectors...
  22. pmc Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells
    Yunching Chen
    Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Mol Pharm 6:696-705. 2009
    ..Thus, DSGLA served as both a formulation component as well as a therapeutic agent which synergistically enhanced the activity of siRNA...
  23. pmc Biodistribution studies of nanoparticles using fluorescence imaging: a qualitative or quantitative method?
    Yang Liu
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 1315 Kerr Hall CB 7571, Chapel Hill, North Carolina 27599 7571, USA
    Pharm Res 29:3273-7. 2012
    ..The biodistribution of Lipid/Calcium/Phosphate (LCP) nanoparticles (NPs) in tumor-bearing mice was investigated using fluorescence imaging. A quantitative validation of this method was done by (3)H and (111)In labeling of the nanoparticles...
  24. pmc Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor
    Jun Li
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Control Release 158:108-14. 2012
    ..Bio-distribution study showed that LCP-II required more PEGylation for MPS evasion than the previous LPD, probably due to increased surface curvature in LCP-II...
  25. pmc Nanoparticle delivery of a peptide targeting EGFR signaling
    Sang Kyoon Kim
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    J Control Release 157:279-86. 2012
    ..Our findings offer proof-of-concept for an intracellular peptide-mediated cancer therapy that is delivered by carefully designed nanoparticles...
  26. ncbi request reprint Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy
    Yunching Chen
    University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, Division of Molecular Pharmaceutics, Campus Box 7360 Kerr Hall, Chapel Hill, NC 27599, USA
    Expert Opin Drug Deliv 5:1301-11. 2008
    ..This review summarizes different signaling pathways inhibited by siRNA and the advantages of targeted siRNA as a delivery system...
  27. pmc Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy
    Yunching Chen
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Mol Ther 18:1650-6. 2010
    ..When miR-34a and siRNAs were co-formulated in GC4-targeted nanoparticles, an enhanced anticancer effect was observed...
  28. pmc Targeted delivery of EV peptide to tumor cell cytoplasm using lipid coated calcium carbonate nanoparticles
    Sang Kyoon Kim
    Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Cancer Lett 334:311-8. 2013
    ..LCC NPs also mediated the specific delivery of Alexa-488-EV peptide to tumor tissue in vivo, provoking a high tumor growth retardation effect with minimal uptake by external organs and no toxic effects...
  29. pmc Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles
    Shyh Dar Li
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    J Control Release 126:77-84. 2008
    ..It resulted in 70-80% gene silencing in the metastasis model after a single i.v. injection (150 microg siRNA/kg). This effective formulation also showed very little immunotoxicity...
  30. pmc Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy
    Srinivas Ramishetti
    Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    Ther Deliv 3:1429-45. 2012
    ..In this article, their design, as well as their multifunctional role in cancer therapy are discussed...
  31. pmc Recent advances in nonviral vectors for gene delivery
    Xia Guo
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 27599, United States
    Acc Chem Res 45:971-9. 2012
    ..We also underscore the value of sustained release of a nucleic acid in this endeavor; making vectors targeted to cells with sustained release in vivo should provide an interesting research challenge...
  32. pmc Dysopsonin activity of serum DNA-binding proteins favorable for gene delivery
    Feng Liu
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599 7360, USA
    J Pharmacol Exp Ther 332:500-4. 2010
    ..The SDBPs with dysopsonin properties and DNA complexes may be further modified and ultimately be developed into a novel DNA carrier system favorable for systemic gene delivery...
  33. pmc Understanding the structure and stability of paclitaxel nanocrystals
    Jiexin Deng
    Division of Molecular Pharmaceutics, University of North Carolina at Chapel Hill, Eshelman School of Pharmacy, 1318 Kerr Hall, Chapel Hill, NC 27599 7360, USA
    Int J Pharm 390:242-9. 2010
    ..Furthermore, we have demonstrated that a higher heating temperature (45 degrees C vs. 37 degrees C) used in the incubation-sonication procedure was able to provide even better nanocrystal stability for long periods of incubation time...
  34. pmc Lipid-based systemic delivery of siRNA
    Yu Cheng Tseng
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    Adv Drug Deliv Rev 61:721-31. 2009
    ..At the end, we discuss different strategies to overcome these barriers, especially focusing on the step of endosome escape. Toxicity issues and current successful examples for lipid-based delivery are also included in the review...
  35. pmc In vivo gene delivery by nonviral vectors: overcoming hurdles?
    Yuan Zhang
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7571, USA
    Mol Ther 20:1298-304. 2012
    ..We will also introduce the current progress in the design of nonviral vectors, and briefly discuss their safety issues...
  36. pmc Trp2 peptide vaccine adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model
    Elizabeth A Vasievich
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Mol Pharm 9:261-8. 2012
    ..Thus, (R)-DOTAP has shown the ability to break tolerance as an adjuvant. Its activity to enhance immunogenicity of other tumor associated antigens should be studied further...
  37. ncbi request reprint Self-assembled lipid nanomedicines for siRNA tumor targeting
    Yu Cheng Tseng
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    J Biomed Nanotechnol 5:351-63. 2009
    ..At the end, we show that multifunctional self-assembled lipid-based nanoparticles could also be versatile delivery vehicles for cancer molecular imaging probes...
  38. ncbi request reprint Mechanism of naked DNA clearance after intravenous injection
    Feng Liu
    Division of Molecular Pharmaceutics, University of North Carolina School of Pharmacy, Chapel Hill, NC 27599, USA
    J Gene Med 9:613-9. 2007
    ..Naked DNA after intravenous (i.v.) injection will be taken up by the liver and depredated by serum nucleases...
  39. ncbi request reprint A simple but effective cancer vaccine consisting of an antigen and a cationic lipid
    Weihsu Chen
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina at Chapel Hill, 2316 Kerr Hall, CB 7360, Chapel Hill, NC 27599, USA
    Cancer Immunol Immunother 57:517-30. 2008
    ..Overall, these results indicate that cationic lipid DOTAP alone serves as an efficient vaccine adjuvant for the induction of a therapeutic, antigen-specific anti-cancer activity...
  40. doi request reprint Multifunctional nanoparticles co-delivering Trp2 peptide and CpG adjuvant induce potent cytotoxic T-lymphocyte response against melanoma and its lung metastasis
    Zhenghong Xu
    Division of Molecular Pharmaceutics, Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Control Release 172:259-65. 2013
    ..Thus, encapsulation of phospho-peptide antigens into LCP may be a promising strategy for enhancing the immunogenicity of poorly immunogenic self-antigens for cancer therapy. ..
  41. ncbi request reprint Extraction issues of paclitaxel in nanocrystals
    Jiexin Deng
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7360, USA
    J Biomed Nanotechnol 6:198-201. 2010
    ..We hope that our findings would highlight certain issues to be aware of when conducting PK and biodistribution studies for nano-drug carriers...
  42. doi request reprint The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides
    Leaf Huang
    Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    J Drug Target 18:567-74. 2010
    ..We also reprise several recent studies that have examined the inter-relationship of size and shape in influencing delivery...
  43. doi request reprint Lipid-coated Cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy
    Shutao Guo
    Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
    ACS Nano 7:9896-904. 2013
    ..By simultaneously promoting an increase in cytotoxicity and a lesser degree of side effects over free CDDP, CDDP NPs show great therapeutic potential with lower doses of drug while enhancing anticancer effectiveness. ..
  44. doi request reprint Lipid-based vectors for siRNA delivery
    Shubiao Zhang
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Drug Target 20:724-35. 2012
    ..More complex self-assembly structures, such as LPD (LPH) and LCP, may provide a good solution to siRNA delivery. They have demonstrated controlled particle morphology and size and siRNA delivery activity for both in vitro and in vivo...
  45. doi request reprint Cancer immunotherapy and nanomedicine
    Wei Yun Sheng
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 1319 Kerr Hall, Chapel Hill, North Carolina 27599, USA
    Pharm Res 28:200-14. 2011
    ..This review will discuss the relationships between the tumor and the immune system, and also will include topics covering the strategies used in eliminating tumors by using nanomedicine...
  46. ncbi request reprint Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines
    Weili Yan
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    Mol Immunol 44:3672-81. 2007
    ..Our data elucidated one important mechanism of adjuvant activity of cationic liposome and could facilitate rational design of synthetic lipid based adjuvants...
  47. doi request reprint Enantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine
    Elizabeth A Vasievich
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, NC 27599, USA
    Cancer Immunol Immunother 60:629-38. 2011
    ..The results show the DOTAP enantiomers act differently as adjuvants in vivo, with (R)-DOTAP being more effective at stimulating a CD8(+) anti-tumor response...
  48. pmc Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands
    Osamu Nakagawa
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 1072 Genetic Medicine Building, Chapel Hill, North Carolina 27599, USA
    J Am Chem Soc 132:8848-9. 2010
    ..Significant biological effects were attained in the sub-100 nM concentration range...
  49. doi request reprint Bryostatin-I: a dendritic cell stimulator for chemokines induction and a promising adjuvant for a peptide based cancer vaccine
    Weili Yan
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    Cytokine 52:238-44. 2010
    ..In conclusion, for the first time, we demonstrated that Bryo-I induced chemokine release from dendritic cell and was an effective adjuvant for peptide cancer vaccine...
  50. doi request reprint The suppressive tumor microenvironment: a challenge in cancer immunotherapy
    Elizabeth A Vasievich
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Mol Pharm 8:635-41. 2011
    ..We see gene therapy as the most innovative and flexible method to lead the charge to specifically modifying the tumor microenvironment...
  51. ncbi request reprint Mechanism of in vivo DNA transport into cells by electroporation: electrophoresis across the plasma membrane may not be involved
    Feng Liu
    School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA
    J Gene Med 8:353-61. 2006
    ..In this study, we have designed a device and experiments to test the hypothesis...
  52. pmc Anti-tumor activity of splice-switching oligonucleotides
    John A Bauman
    Department of Pharmacology and Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA
    Nucleic Acids Res 38:8348-56. 2010
    ..Our findings demonstrate in vivo anti-tumor activity of SSOs that modulate Bcl-x pre-mRNA splicing...
  53. doi request reprint Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery
    Yuhua Wang
    Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, USA Electronic address
    J Control Release 172:179-89. 2013
    ..The exploitation of TH in the NP formulation exhibited a biocompatibility profile similar to that of protamine, with minimal immunostimulating and systemic toxicity observed after repeated administration. ..
  54. doi request reprint Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy
    Shutao Guo
    Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Control Release 174:137-42. 2014
    ..Thus, CDDP precipitate serves as the major material for assembling the novel NPs. This unique method of nanoparticle synthesis may be applicable in formulating other insoluble drugs. ..
  55. pmc Turning an antiviral into an anticancer drug: nanoparticle delivery of acyclovir monophosphate
    Jing Yao
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    J Control Release 170:414-20. 2013
    ..In conclusion, with the help of LCP NPs, monophosphorylation modification of ACV can successfully modify an HSV-TK-dependent antiviral drug into an anti-tumor drug...
  56. pmc Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis
    Yuhua Wang
    Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Mol Ther 21:1919-29. 2013
    ..Our findings indicate CD47 as a potential prognostic marker for melanoma development as well as a target for therapeutic intervention with RNAi-based nanomedicines...
  57. ncbi request reprint Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells
    Shyh Dar Li
    Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina at Chapel Hill, North Carolina 27599, USA
    Mol Pharm 3:579-88. 2006
    ..Our results suggest that the ligand targeted and sterically stabilized nanoparticles can provide a selective delivery of AS-ODN and siRNA into lung cancer cells for therapy...
  58. pmc Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC
    Yuan Zhang
    Division of Molecular Pharmaceutics and Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7571, USA
    Mol Ther 21:1559-69. 2013
    ....
  59. ncbi request reprint Novel nonviral vectors target cellular signaling pathways: regulated gene expression and reduced toxicity
    Feng Liu
    Division of Molecular Pharmaceutics, University of North Carolina School of Pharmacy, 1318 Kerr Hall, CB 7360, Chapel Hill, NC 27599 7360, USA
    J Pharmacol Exp Ther 321:777-83. 2007
    ..Overall, these examples provide hope that free ligand can be used to effectively mediate cellular processes to overcome some of the obstacles limiting the success of gene therapy...
  60. doi request reprint Strategies on the nuclear-targeted delivery of genes
    Jing Yao
    Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA and
    J Drug Target 21:926-39. 2013
    ..The resulting technology may also enhance delivery of other macromolecules to the nucleus...
  61. doi request reprint Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy
    Yuan Zhang
    Division of Molecular Pharmaceutics, Center for Nanotechnology in Drug Delivery, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Biomaterials 34:8459-68. 2013
    ..Co-encapsulation of an oncogene-modulating siRNA and a chemotherapeutic agent will allow simultaneous interruption of diverse anti-cancer pathways, leading to increased therapeutic efficacy and reduced toxicities...

Research Grants7

  1. Interaction of cationic lipids with dendritic cells
    Leaf Huang; Fiscal Year: 2010
    ..Project will study the activity and the mechanism of the lipid adjuvant, in order to find more active lipid and more efficacious vaccine. ..
  2. LPD Nanoparticles in Anti-Cancer Therapy
    Leaf Huang; Fiscal Year: 2010
    ..A self-assembled nanoparticle formulation will be used as a delivery vehicle. The project uses lung cancer and lung metastasis in mice as the disease model. ..
  3. Novel nanoparticles for siRNA delivery
    Leaf Huang; Fiscal Year: 2010
    ..The other is to transport siRNA to tumors with not-so-leaky vasculature. If successful, the project will significantly advance siRNA as cancer therapeutics. ..